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Abstract
Background: The aim of this article is to explore ways in which selection bias and ascertainment
bias can be reduced and investigated in trials, by using the example of a drug trial carried out in
both developed and developing countries in hospital delivery wards.  
Methods: We describe an innovative and practical design for the boxes for packing the drugs as a
way of increasing the security of allocation concealment and blinding.  We also assess
ascertainment bias using sensitivity analyses, as some unblinding could have occurred due to a
potential side effect of one of the drugs.
Results: The sensitivity analyses indicated that the conclusions about the relative effects of the
treatments could be maintained even in the unlikely worst-case scenarios. 
Conclusions: Detailed description of the procedures protecting against common biases and of the
assessment of ascertainment bias in this trial should allow readers to confidently appraise and
interpret the results obtained. In addition, our experiences will assist others in planning trials in the
future.
Background
In the attempt to reduce the risk of bias in clinical trials,
the method used to assign treatments to trial participants
is crucial for reducing selection bias. Randomisation is the
method of choice, and also permits the use of probability
theory to express the likelihood that any difference in out-
come between treatment groups merely reflects chance.
Successful randomisation in practice depends both on
adequately generating an unpredictable allocation
sequence, and also on concealing that sequence until
Published: 03 October 2003
BMC Medical Research Methodology 2003, 3:19
Received: 28 June 2003
Accepted: 03 October 2003
This article is available from: http://www.biomedcentral.com/1471-2288/3/19
© 2003 Piaggio et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.
BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/19
Page 2 of 7
(page number not for citation purposes)
assignment occurs [1,2]. Blinding the identity of treat-
ments to the investigators, participants, and evaluators
(sometimes using placebo) also reduces the risk of bias
after assignment of treatments. Knowledge of treatment allo-
cation could lead to selective withdrawals before the treat-
ment starts, selective loss to follow-up (both selection
biases) and/or to a subjective assessment of the outcome
(ascertainment bias).
Inadequate methodological reporting of randomised clin-
ical trials (RCTs) is associated with bias in the estimation
of treatment effects [3]. Incomplete or inaccurate report-
ing impairs the critical appraisal of the quality of clinical
trials, which is important to assess the validity of the
results of the individual trial and in conducting systematic
reviews. This realisation has been a factor in the recent
calls for full and clear reporting of trials. To address these
issues, the CONSORT statement [4] was published in
1996 and comprises a checklist, for two-group parallel
designs, of essential items that should be included in
reports of RCTs and a diagram to document the flow of
participants through the trial. This has been accepted by
many editors of international journals, and recently been
revised [5] with further explanation and elaboration [6]. It
is also being extended to other trial designs http://
www.consort-statement.org. Nevertheless, concentration
in Journals on the clinical issues often restricts the ability
of those planning new trials to learn from the experiences
of innovative methods gained in completed trials.
Hence the aim of this paper is to use the World Health
Organization (WHO) Misoprostol Third Stage of Labour
Trial in the Management of the Third Stage of Labour [7]
as a case study to fully describe the details of procedures
for sequence generation, allocation concealment and
blinding in the context of a large equivalence RCT con-
ducted in both developing and developed countries. We
also describe how we evaluated the success of blinding by
assessing the existence of ascertainment bias in the main
outcomes due to differential side-effects in the two
treatments.
Presentation of the Trial and its Procedures
The WHO Misoprostol Third Stage of Labour Trial
The incidence of postpartum haemorrhage can be reduced
by the use of injectable uterotonic agents in the manage-
ment of the third stage of labour (the period in which the
placenta is delivered). However, some of those injectable
agents (mostly ergot alkaloids) are associated with side-
effects. An alternative is misoprostol, a prostaglandin E1
analogue that has strong uterotonic effects and was
regarded as a promising agent for use in the third stage of
labour in some uncontrolled unblinded studies [8,9]. It is
administered orally or vaginally rather than intravenously
(IV) or intramuscularly (IM) and therefore it could be
used more easily than injectable preparations.
The aim of the WHO Misoprostol Third Stage of Labour
Trial was to evaluate the effectiveness of routine oral mis-
oprostol in the management of the third stage of labour,
as compared with one of the injectable preparations, oxy-
tocin. The trial was a multicentre, double-blind, ran-
domised controlled trial conducted to determine whether
the efficacy of 600 mcg misoprostol orally for use during
the third stage of labour (after the baby is born) is equiv-
alent to that of 10 IU of oxytocin in terms of measured
postpartum vaginal blood loss of 1000 mls or more and
the use of additional uterotonics, without an unaccepta-
ble level of side-effects. It was conducted in 14 hospitals
in Argentina, China, Egypt, Ireland, Nigeria, South Africa,
Switzerland, Thailand and Viet Nam. Women about to
deliver vaginally were randomly allocated to receive 600
mcg misoprostol orally or 10 IU oxytocin (IV or IM) with
corresponding identical placebos. The medications were
administered immediately after delivery of the baby as
part of the active management of the third stage of labour.
A total of 18530 women were randomised into the trial
(9264 women allocated to the misoprostol group and
9266 allocated to the oxytocin group), between April
1998 and November 1999. The two primary outcomes
were the postpartum vaginal blood loss of 1000 mls or
more measured from the time of delivery of the baby until
the mother was transferred to postnatal care, and the use
of additional uterotonics. Information about the primary
outcomes was available for 99% of randomised women.
Oral misoprostol was associated with a higher occurrence
of measured blood loss ≥ 1000 ml (risk difference 1.1%,
95% CI 0.6 to 1.6, relative risk RR = 1.39, 95% CI 1.19 to
1.63) and with more frequent use of additional uteroton-
ics (risk difference 4.3%, 95% CI 3.3 to 5.3, RR = 1.40,
95% CI 1.29 to 1.51).
Sequence Generation, Allocation Concealment and 
Blinding
Sequence generation
The randomisation sequence was produced centrally in
Geneva by the Clinical Trials and Informatics (CTI) sup-
port unit of RHR/WHO. Randomisation was stratified by
country, allocating subjects to the two groups in blocks of
randomly varying sizes of 4 and 6. For each country, ran-
dom permutations in the blocks were produced using a
SAS® random number generator, with the starting number
taken as a multiple of the WHO centre number (an iden-
tifying code number for the participating centre in the
country). The SAS® program that produces this allocation
for a particular country is included in the Appendix (see
Additional file: 1.
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Allocation concealment
Allocation concealment was carefully planned to reduce
selection bias through the design of special treatment-
packs and dispensers [7].
Treatment packs contained three tablets, one ampoule,
one syringe with a needle and swabs for injection and
were identical, except for the centre identification and the
subject number on the label (Figure 1).
The participating centres were in many areas of the world
– some with poor telecommunications systems. This
meant that central telephone randomisation was not
always a feasible option. Hence, to preserve the allocation
sequence, to conceal it, and to organize the distribution of
the treatment packs, we arranged these in sequential order
of subject numbers in bigger containers, or 'dispensers', in
sets of 25. Each dispenser was sealed at the top and had a
sealed slot at the bottom to be ripped open in order to
remove the individual treatment packs sequentially, with
lower numbers removed first. Each dispenser was labelled
with the WHO project number and name, the country
identification, the packing date and the range of sequen-
tial subject numbers on the treatment packs included (Fig-
ure 2).
In each hospital, there was at least one researcher (usually
a nurse or a midwife) who had been trained to act as a
focal point for the trial in that hospital. When a woman
had been admitted after screening and vaginal delivery
was imminent, this researcher removed a pack from the
dispenser through the bottom open slot, starting with dis-
pensers in ascending order of subject numbers. She wrote
the woman's name on the pack. She also wrote the
woman's name and her hospital record number on the
appropriate line of a subject number list provided by the
CTI Unit. At this moment the woman was considered as
randomised and entered into the trial. The WHO site vis-
itor (or in his absence, the study country co-ordinator)
verified that all names on the subject number list had
numbers assigned in sequence. He also verified that the
Treatment packFigure 1
Treatment pack
Dispenser (where the top seal has been violated)Figure 2
Dispenser (where the top seal has been violated)
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dispensers were used in order of subject numbers and that
the used dispensers had been opened by the bottom slot
and the top seal had not been removed. Used packs and
dispensers were discarded after observation. Unused
packs were returned to Geneva. The randomisation
sequence was thus preserved in every hospital. This alloca-
tion system of treatment packs contained by dispensers
proved reliable and convenient, even in developing coun-
try settings.
Blinding
Double-blinding implied making placebo vials identical
to oxytocin vials for women assigned misoprostol and
placebo tablets identical to misoprostol tablets for
women assigned oxytocin. A drug company preparing
vials with 10 IU of oxytocin also prepared identical pla-
cebo vials. Another drug company prepared misoprostol
200 mcg and identical placebo tablets. In the oxytocin
group, the vial contained 10 IU of oxytocin and the tablets
were placebo. In the misoprostol group, the vial con-
tained placebo liquid and the tablets contained 200 mcg
of misoprostol each. The treatment packs were thus iden-
tical in shape, colour, weight and feel. The participants,
those administering the interventions and those assessing
the outcomes were all blinded to the group assignments.
The schedule of group assignments was kept in Geneva
blinded from the trial co-ordinators. Unblinding for med-
ical reasons was possible by requesting the trial co-ordina-
tor in Geneva to reveal the code, but there were no such
cases.
Evaluation of Ascertainment Bias Due to Unblinding by a 
Side-Effect
Oxytocin alone when used in the management of the
third stage of labour is relatively free of side-effects,
although it carries the discomfort of injection. Ergot
preparations, alone or in combination with oxytocin,
cause significant rise in blood pressure, but oxytocin
alone is not hypertensive. On the other hand, an associa-
tion between misoprostol and shivering and other pros-
taglandin-related side effects (i.e. nausea, vomiting,
diarrhoea) after administration has been reported. [8–
12]. Some degree of unblinding could, therefore, have
occurred due to the knowledge of differential side-effects.
If shivering, the most prevalent of the side-effects, starts
before blood loss measurement is completed, the chance
of the assessor correctly guessing the treatment assign-
ment could have been more than the 50% expected by
chance in the absence of knowledge about the association.
The chance of a correct guess is however unlikely to be
close to 100% because shivering also occurs with delivery
in a minority of women regardless of misoprostol.
Adequate correction for ascertainment bias requires
knowledge of the degree of mis-estimation of blood loss
in women with shivering. This quantity cannot be esti-
mated from the data because high levels of blood loss in
women with shivering could be a consequence of ascer-
tainment bias, but they could also be due to a real biolog-
ical effect of misoprostol on blood loss that takes place
through shivering.
We therefore performed sensitivity analyses considering
the effects of a range of plausible values of the ascertain-
ment bias in the treatment effect. We assumed that the
blood loss of all women with shivering, when measured,
was inflated by 100, 200, 300, 400 or 500 mls or
decreased by the same amounts. Then we re-analyzed the
data subtracting these quantities from all measured blood
losses in women with shivering and then repeated the
analyses adding the same quantities to the measurements.
If a negative value was obtained when subtracting, the
blood loss was set to zero. These re-analyses have the
advantage, compared to those we reported previously [7],
that they use all women included in the main analysis and
do not introduce selection bias. They also deal with possi-
ble bias in either direction.
The results of these sensitivity analyses indicate that even
in the unlikely worst-case scenarios in which blood loss
measurements in women with shivering had been inflated
or decreased by 500 mls, the conclusions about the rela-
tive advantages of oxytocin would not change (Table 1).
Comments
Reporting of the main clinical findings of a trial in a Jour-
nal does not always provide sufficient details for others to
learn innovative methods from the experience. Indeed,
extra clinical questions may be raised after publication of
the original report, and further analyses may appear in
correspondence columns to aid clinical readers, as for this
trial [13–17]. Similarly, publication of the methodological
procedures we used for bias reduction and for assessing
this bias will be useful for other trialists. Our method of
randomisation ensured the generation of an unpredicta-
ble assignment sequence for treatment allocation. This
was guaranteed by the sequence being centrally produced
and by the use of blocks of randomly varying sizes. Blocks
of 4 or 6 are small, but this size is reasonable, considering
the effective double-blinding [18,19]. Randomization was
successful in achieving a balance in baseline variables, for
which descriptive statistics were similar between groups
[7].
The range of clinical settings for the Misoprostol Third
Stage of Labour Trial posed special challenges in achieving
the concealment of the allocation and double-blinding.
Allocation concealment required the design of identically
appearing boxes and dispensers. The dispensers ensured
the preservation of the random sequence and avoided the
BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/19
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loss of treatment packs in busy labour wards. A subject
number list was kept, verifying that names were not
wrongly entered or omitted. We believe that the conceal-
ment of the allocation sequence was carefully planned
and thus prevented selection bias.
Double-blinding was complicated to implement because
it implied producing placebo vials identical to the oxy-
tocin vials, as well as placebo tablets identical to the mis-
oprostol tablets. Actually, of the eight randomised
controlled trials published to date comparing misoprostol
to other uterotonics, only four trials were double-blind
[10]. We considered it important to have this feature of
double-blinding in the trial to prevent selection bias after
assigning the treatment, ascertainment bias and bias due
to differential use of a co-intervention. The use of misopr-
ostol implied changing the routine practice of the hospi-
tal, and unblinded medical personnel could feel inclined
to change the treatment of a woman assigned misoprostol
to the routine uterotonic if the woman had a risk condi-
tion. They could also be inclined to do the reverse, given
that misoprostol is such a popular drug in obstetrics and
gynaecology [8,9] and it was therefore expected to per-
form equally or better than injectable uterotonics. This
could introduce selection bias. Ascertainment bias was
likely to occur when measuring blood loss if researchers
were unblinded, for similar reasons. Providing additional
uterotonics as a co-intervention more frequently to
women receiving the new treatment could introduce bias
in the effect of the treatment on the use of additional uter-
otonics and also on blood loss, since the additional uter-
otonics could prevent further blood loss. Ascertainment
bias would be also possible in the assessment of side-
effects, due to the known association between misopros-
tol and shivering and other prostaglandin-related clinical
events.
Table 1: Sensitivity analyses for measured blood loss ≥ 1000 ml (severe post-partum haemorrhage, or SPPH)
Assumed bias introduced
in SPPH by unblinding
due to shivering (mls)
Group No. of 
women
No. of cases % RR 95% CI
500 Misoprostol 9214 295 3.2 1.23 (1.04 to 1.45)
Oxytocin 9228 241 2.6
400 Misoprostol 9214 307 3.3 1.27 (1.07 to 1.49)
Oxytocin 9228 243 2.6
300 Misoprostol 9214 313 3.4 1.29 (1.09 to 1.52)
Oxytocin 9228 243 2.6
200 Misoprostol 9214 322 3.5 1.28 (1.09 to 1.51)
Oxytocin 9228 251 2.7
100 Misoprostol 9214 334 3.6 1.31 (1.11 to 1.53)
Oxytocin 9228 256 2.8
0 Misoprostol 9214 366 4.0 1.39 (1.19 to 1.63)
Oxytocin 9228 263 2.9
-100 Misoprostol 9214 401 4.4 1.50 (1.29 to 1.75)
Oxytocin 9228 267 2.9
-200 Misoprostol 9214 453 4.9 1.64 (1.41 to 1.90)
Oxytocin 9228 277 3.0
-300 Misoprostol 9214 499 5.42 1.74 (1.51 to 2.00)
Oxytocin 9228 288 3.12
-400 Misoprostol 9214 591 6.41 1.94 (1.70 to 2.22)
Oxytocin 9228 305 3.31
-500 Misoprostol 9214 688 7.47 2.10 (1.85 to 2.39)
Oxytocin 9228 328 3.55
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Blinding of all involved in implementing the trial was
achieved by the identical appearance of the boxes and
their contents, including double placebos. There were no
cases of unblinding for medical reasons because it was not
necessary to know the treatment assignment in order to
provide additional uterotonics or any other additional
treatment. We believe double-blinding successfully pre-
vented possible biases likely to occur after treatment
assignment.
We could have assessed the success of the blinding by
interviews to the medical personnel, asking questions
about which treatment they thought was being adminis-
tered, and then evaluating if they were guessing better
than chance. We did not apply this procedure for three
reasons. In the first place, the interviews, even if short,
would have disturbed even more the medical practice in
the delivery ward. In the second place, the possibility of
inaccurate responses or interpretation difficulties follow-
ing tests of blindness has led to their usefulness being
characterised as being "tests of hunches for adverse effects
or efficacy" [20,21]. Third, blinding in the particular case
of equivalence trials does not protect against bias towards
demonstrating equivalence, since it does not prevent a cli-
nician taking similar measures of blood or applying a co-
intervention in the two arms [22].
In spite of the blinding efforts, we recognized there could
be some ascertainment bias in the main outcomes due to
unblinding by guessing the treatment allocation due to
shivering. We conducted sensitivity analyses to evaluate
the magnitude of this possible bias, and concluded that
even if present, this bias would not substantially alter the
main conclusions from the trial.
Trial boxes are often used for ease of administration of the
trial medications, ease of enrolment and to achieve satis-
factory concealment of the allocation sequence. The dis-
pensers we designed also served the practical purpose of
administering drug distribution in the hospital wards and
to facilitate enrolment of eligible women, by making
them available all the time. This strategy could be used by
other researchers in future trials. Especially in some set-
tings in developing countries or busy wards or rural insti-
tutions in developing or developed countries, this type of
administration of trial medications is a good alternative to
central/telephone information of the treatment
allocation.
The detailed description of the procedures for protecting
against common biases in RCTs in this case study should
allow readers the confidence to critically appraise and
interpret the results of this trial. In addition, our experi-
ences will assist others in planning trials in the future.
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